Try our beta test site

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer (HELOISE)

This study has been terminated.
(futility following planned interim analysis)
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01450696
First received: October 10, 2011
Last updated: October 5, 2016
Last verified: October 2016
  Purpose
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6 mg/kg every 3 weeks (q3w) as standard of care or an 8-mg/kg loading dose followed by 10 mg/kg q3w until disease progression. Capecitabine will be administered for 6 cycles at a dose of 800 milligrams per meter-squared (mg/m^2) orally twice a day on Days 1 to 14 of each 3-week cycle, and cisplatin will be administered intravenously for 6 cycles at a dose of 80 mg/m^2 on Day 1 of each 3-week cycle. Herceptin will be continued until disease progression occurs.

Condition Intervention Phase
Gastric Cancer
Drug: Capecitabine
Drug: Cisplatin
Drug: Herceptin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Multicenter Phase IIIb Study Comparing Two Trastuzumab Dosing Regimens, Each in Combination With Cisplatin/Capecitabine Chemotherapy, as First-Line Therapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment for Metastatic Disease

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of Participants Who Died - FAS [ Time Frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.

  • Overall Survival - FAS [ Time Frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.


Secondary Outcome Measures:
  • Percentage of Participants Who Died - Per Protocol Set (PPS) [ Time Frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

  • Overall Survival - PPS [ Time Frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

  • Percentage of Participants With Disease Progression or Death - PPS [ Time Frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

  • Progression-Free Survival - PPS [ Time Frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

  • Percentage of Participants With Objective Response - PPS [ Time Frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015) ]
    Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to <10 mm. PR was defined as a ≥30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.

  • Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS [ Time Frame: Day 21 of Cycle 1, 2, 3, 4, 5, 7, 9, 11 (cycle length = 21 days) ]
    Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in μg/mL.

  • Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS [ Time Frame: Pre-dose (0 minutes) and within 15 minutes after end of 2-hour Herceptin infusion on Day 1 of Cycle 1 (cycle length = 21 days) ]
    Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in μg/mL.


Enrollment: 296
Study Start Date: December 2011
Study Completion Date: August 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Capecitabine + Cisplatin + Herceptin (6 mg/kg)
Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Drug: Capecitabine
Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Drug: Cisplatin
Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Drug: Herceptin
Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Other Name: Trastuzumab
Experimental: Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Drug: Capecitabine
Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Drug: Cisplatin
Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Drug: Herceptin
Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Other Name: Trastuzumab

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with metastatic disease documented to involve at least liver or lung or both
  • Measurable disease according to RECIST Version 1.1 or non-measurable evaluable disease
  • At least 2 organs involved in metastatic gastric tumor (including at least lung or liver or both) in addition to the site of primary tumor, where metastasis in distant lymph nodes, peritoneal metastasis, and malignant pleural effusion may count as "organs" in this context
  • HER2-positive primary or metastatic tumor as assessed by central laboratory
  • Adequate renal function (creatinine clearance greater than equal to (≥) 45 milliliters per minute [mL/min])
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2

Exclusion Criteria:

  • Previous chemotherapy for locally advanced or metastatic disease
  • Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
  • Prior therapy with an anti-HER2 agent and/or platinum-based chemotherapeutic agent
  • Residual relevant toxicity resulting from previous therapy
  • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (such as jejunostomy probe and gastric or jejunostomy tubes) which may impair the ability to administer or absorb capecitabine
  • Current (significant or uncontrolled) gastrointestinal bleeding
  • Other malignancy within the last 5 years, except for carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin
  • History of documented congestive heart failure, angina pectoris requiring medication, electrocardiogram (ECG) evidence of transmural myocardial infraction, poorly controlled hypertension, clinically significant valvular heart disease, or high-risk uncontrollable arrhythmias
  • Baseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
  • Chronic or high-dose corticosteroid therapy
  • History or clinical evidence of brain metastases
  • Pregnant women
  • Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01450696

  Hide Study Locations
Locations
United States, California
La Jolla, California, United States, 92093
Los Angeles, California, United States, 90033
Whittier, California, United States, 90603
Whittier, California, United States, 90606
United States, Indiana
Goshen, Indiana, United States, 46526
United States, Kansas
Wichita, Kansas, United States, 67214-3728
United States, New York
New York, New York, United States, 10065
United States, Oregon
Portland, Oregon, United States, 97239
United States, South Carolina
Charleston, South Carolina, United States, 29425
Australia, New South Wales
Port Macquarie, New South Wales, Australia, 2444
Wahroonga, New South Wales, Australia, 2076
Australia, South Australia
Woodville South, South Australia, Australia, 5011
Australia, Western Australia
Murdoch, Western Australia, Australia, 6150
Bosnia and Herzegovina
Banja Luka, Bosnia and Herzegovina, 78000
Sarajewo, Bosnia and Herzegovina, 71000
Brazil
Rio de Janeiro, RJ, Brazil, 20560-120
Porto Alegre, RS, Brazil, 90610-000
Barretos, SP, Brazil, 14784-400
Sao Paulo, SP, Brazil, 01246-000
Sorocaba, SP, Brazil, 18030-245
Chile
Santiago, Chile, 7500921
Santiago, Chile, 8380456
Viña del Mar, Chile, 2520612
China
Beijing, China, 100050
Beijing, China, 100071
Beijing, China, 100142
Beijing, China, 100853
Changchun, China, 130012
Changsha, China, 410006
Changzhou, China, 213003
Guangzhou, China, 510060
Hangzhou, China, 310016
Nanjing, China
Shanghai, China, 200032
Wuhan, China, 430030
Zhengzhou, China, 450008
Czech Republic
Brno, Czech Republic, 656 53
Olomouc, Czech Republic, 775 20
Praha 2, Czech Republic, 128 08
Praha 8, Czech Republic, 180 81
Germany
Berlin, Germany, 10117
Frankfurt, Germany, 60488
Mannheim, Germany, 68167
Hungary
Budapest, Hungary, 1097
Budapest, Hungary, 1145
Pecs, Hungary, 7623
Szolnok, Hungary, 5004
Szombathely, Hungary, 9700
Veszprem, Hungary, 8200
Italy
Catanzaro, Calabria, Italy, 88100
Napoli, Campania, Italy, 80131
Bologna, Emilia-Romagna, Italy, 40138
Reggio Emilia, Emilia-Romagna, Italy, 42100
Udine, Friuli-Venezia Giulia, Italy, 33100
Milano, Lombardia, Italy, 20133
Ancona, Marche, Italy, 60121
Florence, Toscana, Italy, 50124
Pisa, Toscana, Italy, 56100
Korea, Republic of
Bundang City, Korea, Republic of, 463-802
Incheon, Korea, Republic of, 405-760
Seoul, Korea, Republic of, 03722
Seoul, Korea, Republic of, 06351
Seoul, Korea, Republic of, 110-744
Seoul, Korea, Republic of, 130-872
Seoul, Korea, Republic of, 135-720
Mexico
Distrito Federal, Mexico, 14080
Mexico City, Mexico, 06760
Monterrey, Mexico, 64020
Oaxaca, Mexico, 68000
New Zealand
Auckland, New Zealand, 1023
Panama
Panama, Panama, 0834-02723
Peru
Arequipa, Peru, 04001
Arequipa, Peru, 5154
Lima, Peru, 1
Lima, Peru, 34
Lima, Peru, Lima 1
Lima, Peru, Lima 41
Trujillo, Peru, 13011
Philippines
Manila, Philippines, 1000
Pasig City, Philippines, 1605
Poland
Krakow, Poland, 31-501
Lublin, Poland, 20-090
Warsaw, Poland, 00-973
Wieliszew, Poland, 05-135
Portugal
Porto, Portugal, 4200-072
Russian Federation
Ivanovo, Russian Federation, 153040
Omsk, Russian Federation, 644013
Ryazan, Russian Federation, 390011
St Petersburg, Russian Federation
Stavropol, Russian Federation, 355045
Tula, Russian Federation, 300053
Serbia
Belgrade, Serbia, 11000
Nis, Serbia, 18000
Sremska Kamenica, Serbia, 21204
South Africa
Bloemfontein, South Africa, 9300
Cape Town, South Africa, 7506
Johannesburg, South Africa, 2193
Spain
Barcelona, Spain, 08035
Barcelona, Spain, 08041
Madrid, Spain, 28046
Turkey
Adana, Turkey, 01250
Gaziantep, Turkey, 27100
Istanbul, Turkey, 34890
Izmir, Turkey, 35100
Izmir, Turkey, 35340
Malatya, Turkey, 44280
Sıhhiye, ANKARA, Turkey, 06100
Ukraine
Cherkassy, Ukraine, 18009
Chernivtsi, Ukraine, 58013
Dnipropetrovsk, Ukraine, 49102
Donetsk, Ukraine, 83092
Kiev, Ukraine, 03115
Lvov, Ukraine, 79031
United Kingdom
Denbighshire, United Kingdom, LL185UJ
Leicester, United Kingdom, LE1 5WW
Southampton, United Kingdom, SO16 6YD
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01450696     History of Changes
Other Study ID Numbers: BO27798
2011-001526-19 ( EudraCT Number )
Study First Received: October 10, 2011
Results First Received: October 5, 2016
Last Updated: October 5, 2016

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Cisplatin
Capecitabine
Trastuzumab
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on March 29, 2017